Affichage 1 à 8 des 8 essais cliniques
|
ESSAI CLINIQUE No essai ClinicalTrials.gov ID |
Investigateur(trice) principal(e)
Coordonnateur(rice) |
||
|---|---|---|---|
|
(EN) A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
LOXO-IDH-20001 NCT04603001  Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Leucémie myéloïde aiguë (LMA) Syndrome myélodysplasique |
Dre Sarit Assouline |
|
(EN) A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis)
CPI-0610-02 NCT02158858 Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Syndrome myélodysplasique |
Dre Shireen Sirhan Chadi Zakaria 514-340-8222 poste 28326 |
|
(EN) A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
CR107947 NCT02598661 Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Syndrome myélodysplasique |
Dre April Shamy Erika Thibault 514-340-8222 |
|
(EN) A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions
ACE-536-MDS-002 NCT03682536 Actif en recrutement
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Syndrome myélodysplasique |
Dr Lambert Busque Julie Trinh Lu 514-252-3400 poste 3336 |
|
Registre Canadien de la SMD
Registre SMD Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Syndrome myélodysplasique |
Dr Robert Delage Linda Vallée 418-649-0252 poste 66602 |
|
Registre de l’hémoglobinurie paroxystique nocturne (HPN)
Registre PNH (M07-001) NCT01374360 Actif en recrutement
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Syndrome myélodysplasique |
Dr Thomas KIss Johanne Blais 514-252-3400 poste 3295 |
|
(EN) A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome
Verona (M15-954) NCT04401748 Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Syndrome myélodysplasique |
Dr Robert Delage Philippe Nadeau 418-649-0252 poste 63501 |
|
(EN) A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
CMBG453B12301 NCT04266301 Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Syndrome myélodysplasique |
Dr Harold J. Olney Sonia Camara 514-890-8444 |
Groupe d'étude en oncologie du Québec